Sucampo Pharmaceuticals Company Profile (NASDAQ:SCMP)

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) announced its earnings results on Wednesday, August, 2nd. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.06. The business had revenue of $59.90 million for the quarter, compared to analysts' expectations of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The company's quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.24 EPS. View Sucampo Pharmaceuticals' Earnings History.

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals issued an update on its FY17 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $1.00-1.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.05. The company issued revenue guidance of $220-230 million, compared to the consensus revenue estimate of $233.60 million.

6 brokers have issued 1 year target prices for Sucampo Pharmaceuticals' shares. Their predictions range from $11.00 to $30.00. On average, they expect Sucampo Pharmaceuticals' stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Sucampo Pharmaceuticals.

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, with acquisition of Vtesse, Sucampo added a late stage program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. The company has lowered its earnings guidance to incorporate the Vtesee acquisition." (7/4/2017)
• 2. Maxim Group analysts commented, "Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $170M in cash & the rest in stock: total of $200M. There is also a contingent earn-out (payments in the mid-single digit to double-digit royalties on global net sales) of the product at increasing net sales levels." (4/3/2017)
• 3. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
• 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Some companies that are related to Sucampo Pharmaceuticals include Dermira (DERM), Acorda Therapeutics (ACOR), Five Prime Therapeutics (FPRX), NeuroDerm (NDRM), Xencor (XNCR), Omeros Corporation (OMER), Athenex (ATNX), Ascendis Pharma A/S (ASND), Retrophin (RTRX), Amarin Corporation PLC (AMRN), ZIOPHARM Oncology (ZIOP), REGENXBIO (RGNX), Intra-Cellular Therapies (ITCI), Keryx Biopharmaceuticals (KERX), Aduro Biotech (ADRO), Vanda Pharmaceuticals (VNDA), Akebia Therapeutics (AKBA) and Reata Pharmaceuticals (RETA).

Sucampo Pharmaceuticals' management team includes the folowing people:

• Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer
• Peter P. Pfreundschuh CPA, Chief Financial Officer, Principal Financial Officer
• Max Donley, Executive Vice President of Human Resources
• Thomas J. Knapp, Executive Vice President, Chief Legal Officer and Corporate Secretary
• Matthias Alder, Executive Vice President
• Stanley G. Miele, Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
• Peter A. Kiener Ph.D., Chief Scientific Officer
• Alex Driggs, Acting General Counsel, Corporate Secretary
• Peter Lichtlen M.D., Ph.D., Chief Medical Officer
• John H. Johnson, Lead Independent Director

Sucampo Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Krensavage Asset Management LLC (6.09%), LSV Asset Management (5.17%), Vanguard Group Inc. (3.56%), Dimensional Fund Advisors LP (3.40%), NEA Management Company LLC (2.71%) and Royce & Associates LP (2.31%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Jason Patrick Meyenburg, Jones W Bryan, Matthias Alder, Peter Greenleaf and Sachiko Kuno. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Cornerstone Capital Management Holdings LLC., GSA Capital Partners LLP, Gotham Asset Management LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, Tudor Investment Corp ET AL and Nationwide Fund Advisors. Company insiders that have sold Sucampo Pharmaceuticals stock in the last year include Andrew P Smith, Daniel P Getman, Matthias Alder, Peter Greenleaf and Sachiko Kuno. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Rubric Capital Management LP, Vanguard Group Inc., Systematic Financial Management LP, Municipal Employees Retirement System of Michigan, Marshall Wace North America L.P., Royce & Associates LP and Bowling Portfolio Management LLC. Company insiders that have bought Sucampo Pharmaceuticals stock in the last two years include Jason Patrick Meyenburg and Jones W Bryan. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $12.10.